OPKO Health, Inc. (OPK)

OPKO Health, Inc. (OPK) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.

Published Reports

OPK-2019-02-28-4Q18
OPK-2018-11-12-3Q18
OPK-2018-08-08-2Q18
OPK-2018-08-06- Somatrogon P3 enrollment completed
OPK-2018-05-21-Non-coverage of Novitas
OPK-2018-05-09-1Q18
OPK-2018-03-02-4Q17
OPK-2017-11-09-3Q17
OPK-2017-10-26-IV VARUBI approved
OPK-2017-10-12-Rayaldee Japan deal
OPK-2017-09-22-VSAR P3 failed
OPK-2017-08-09-2Q17 rev
OPK-2017-06-22-KDIGO guidelines update rev
OPK-2017-06-15-hGH-CTP in adult GHD P3 update rev
OPK-2017-05-18-4Kscore clinical data rev
OPK-2017-05-10-1Q17-rev-2.pdf
OPK-2017-03-02-4Q16 rev2
OPK-2017-01-03-hGH-CTP adult P3 failed rev
opk-2016-11-08-3q16-v2-rev
opk-2016-10-07-palmetto-negative-decision-on-4kscore-lcd-rev
OPK-2016-08-09-2Q16 rev
OPK-2016-06-30-Transition acquisition rev
OPK-2016-06-21-Rayaldee approval-1 rev
OPK-2016-06-16-Analyst day re-cap rev
OPK-2016-06-10-MAC decisions rev
OPK-2016-05-10-1Q16 rev
OPK-2016-05-09-Rayaldee ex-U.S. deal with Vifor Fresenius rev2
OPK-2016-04-27-Rayaldee NDA resubmitted
OPK-2016-03-30-Rayaldee CRL decision
OPK-2016-03-16-MOD-6031 P1 started rev (1)
OPK-2016-03-01-4Q15 rev
OPK-2016-02-23-IV Factor VIIa P2 first patient dosed rev
OPK-2015-11-12-Category I CPT code rev
OPK-2015-11-10-3Q15 rev
OPK-2015-10-14-NDR update
OPK-2015-09-14-Mgnt update
OPK-2015-09-02-Rolapitant approved
OPK-2015-07-08-Initiation-Final